BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sánchez-Bilbao L, Martínez-López D, Revenga M, López-Vázquez Á, Valls-Pascual E, Atienza-Mateo B, Valls-Espinosa B, Maiz-Alonso O, Blanco A, Torre-Salaberri I, Rodríguez-Méndez V, García-Aparicio Á, Veroz-González R, Jovaní V, Peiteado D, Sánchez-Orgaz M, Tomero E, Toyos-Sáenz de Miera FJ, Pinillos V, Aurrecoechea E, Mora Á, Conesa A, Fernández-Prada M, Troyano JA, Calvo-Río V, Demetrio-Pablo R, González-Mazón Í, Hernández JL, Castañeda S, González-Gay MÁ, Blanco R. Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients. J Clin Med 2020;9:E2816. [PMID: 32878150 DOI: 10.3390/jcm9092816] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Pampín-Sánchez R, Martínez-Mugica-Barbosa C, Fonseca-Aizpuru EM, Barbazán-Vázquez FJ, Fernández-González B, Buznego-Súárez L. Outcome of tocilizumab treatment in corticosteroid-resistant thyroid eye disease. Med Clin (Barc) 2022:S0025-7753(22)00311-6. [PMID: 36088128 DOI: 10.1016/j.medcli.2022.05.007] [Reference Citation Analysis]
2 Smith TJ. Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease. The Journal of Clinical Endocrinology & Metabolism 2022;107:S13-26. [DOI: 10.1210/clinem/dgac328] [Reference Citation Analysis]
3 Lu TJ, Amarikwa L, Sears CM, Kossler AL. Advances in the Treatment of Thyroid Eye Disease Associated Extraocular Muscle Myopathy and Optic Neuropathy. Curr Neurol Neurosci Rep 2022. [PMID: 35614367 DOI: 10.1007/s11910-022-01194-7] [Reference Citation Analysis]
4 Wang X, Ye H, Yang S, Sha X, Wang X, Zhang T, Chen R, Xiao W, Yang H. Disulfiram Exerts Antifibrotic and Anti-Inflammatory Therapeutic Effects on Perimysial Orbital Fibroblasts in Graves' Orbitopathy. Int J Mol Sci 2022;23:5261. [PMID: 35563653 DOI: 10.3390/ijms23095261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Atienza-mateo B, Prieto-peña D, Vicente-rabaneda EF, Blanco R, González-gay MA, Castañeda S. Utility of tocilizumab in autoimmune eye diseases. Expert Opinion on Biological Therapy. [DOI: 10.1080/14712598.2022.2066971] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hou J, Tang Y, Chen Y, Chen D. The Role of the Microbiota in Graves' Disease and Graves' Orbitopathy. Front Cell Infect Microbiol 2021;11:739707. [PMID: 35004341 DOI: 10.3389/fcimb.2021.739707] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
7 Elia G, Fallahi P, Ragusa F, Paparo SR, Mazzi V, Benvenga S, Antonelli A, Ferrari SM. Precision Medicine in Graves' Disease and Ophthalmopathy. Front Pharmacol 2021;12:754386. [PMID: 34776972 DOI: 10.3389/fphar.2021.754386] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Mejía González MA, Carbone J. How suitable is intravenous tocilizumab for the treatment of Graves' ophthalmopathy? Expert Rev Clin Immunol 2021;17:1151-3. [PMID: 34704876 DOI: 10.1080/1744666X.2021.1997591] [Reference Citation Analysis]
9 Gupta V, Hammond CL, Roztocil E, Gonzalez MO, Feldon SE, Woeller CF. Thinking inside the box: Current insights into targeting orbital tissue remodeling and inflammation in thyroid eye disease. Surv Ophthalmol 2021:S0039-6257(21)00183-1. [PMID: 34487739 DOI: 10.1016/j.survophthal.2021.08.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Tocilizumab. Reactions Weekly 2021;1856:373-373. [DOI: 10.1007/s40278-021-96366-8] [Reference Citation Analysis]
11 Pérez-Moreiras JV, Varela-Agra M, Prada-Sánchez MC, Prada-Ramallal G. Steroid-Resistant Graves' Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience. J Clin Med 2021;10:706. [PMID: 33670151 DOI: 10.3390/jcm10040706] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
12 Oeverhaus M, Stöhr M, Möller L, Führer D, Eckstein A. Graves' Orbitopathy: Current Concepts for Medical Treatment. Klin Monbl Augenheilkd 2021;238:24-32. [PMID: 33506447 DOI: 10.1055/a-1328-2884] [Reference Citation Analysis]